Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05405309 · ClinicalTrials.gov registry record · Phase 1
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05405309 is a Phase 1 study that was terminated before completion, run by University of Utah. The registered enrollment target is 5 participants.
The verdict
NCT05405309, a Phase 1 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, phase Ib/II study of the combination of RP-3500 and olaparib in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) patients with DDR deficiencies.
Interventions
- DRUG Olaparib
- DRUG RP-3500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2025-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05405309
The ClinicalTrials.gov registry entry for NCT05405309 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olaparib is the first listed.
NCT05405309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05405309 about?
NCT05405309 is a clinical study titled "RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia". This is an open-label, multicenter, phase Ib/II study of the combination of RP-3500 and olaparib in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) patients with DDR deficiencies.
What is the current status of trial NCT05405309?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-09-23. Estimated completion is 2025-01-10.
What interventions are being tested in trial NCT05405309?
The interventions under investigation include: Olaparib (DRUG), RP-3500 (DRUG).
Who is sponsoring clinical trial NCT05405309?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.